# Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis

Study · id `cardio:ct-nct05478161` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05478161](<https://clinicaltrials.gov/study/NCT05478161>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05478161

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.

## Technical summary

Registry record NCT05478161. Allocation not applicable; no masking; primary purpose treatment. Start 2023-01-24 (actual); primary completion 2023-12-20 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 137 participants (enrolled count; ClinicalTrials.gov record NCT05478161, source copy `cardio:ctgov-nct05478161-2026-02-24`, retrieved 2026-10-26)
- Started: 2023-01-24 (actual) (ClinicalTrials.gov record NCT05478161, source copy `cardio:ctgov-nct05478161-2026-02-24`, retrieved 2026-10-26)
- Primary completion: 2023-12-20 (actual) (ClinicalTrials.gov record NCT05478161, source copy `cardio:ctgov-nct05478161-2026-02-24`, retrieved 2026-10-26)
- Completion: 2024-12-17 (actual) (ClinicalTrials.gov record NCT05478161, source copy `cardio:ctgov-nct05478161-2026-02-24`, retrieved 2026-10-26)
- Countries: Germany; Netherlands; Spain (ClinicalTrials.gov record NCT05478161, source copy `cardio:ctgov-nct05478161-2026-02-24`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05478161-2026-02-24`, retrieved 2026-10-26)

## The registry's words

- Brief title: Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis
- Acronym: EMPIRE
- Condition: Transcatheter Aortic Valve Implantation
- Intervention (Device): (ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
- Lead sponsor: NVT GmbH
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)

## Provenance

Content hash: 31fd4bf8a28d299cc52b662d7b6e2df1cd3f8f06995041f873027f6e50908a8a
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
